EP3900701A1 — Composition of pomalidomide for oral dosage form
Assigned to Lotus Pharmaceutical Co Ltd · Expires 2021-10-27 · 5y expired
What this patent protects
The present invention relates to a composition for an oral dosage form of pomalidomide which comprises:- pomalidomide or a pharmaceutically acceptable salt or solvate thereof;- at least one filler which is isomalt;- at least one binder which is pregelatinized starch;- at least on…
USPTO Abstract
The present invention relates to a composition for an oral dosage form of pomalidomide which comprises:- pomalidomide or a pharmaceutically acceptable salt or solvate thereof;- at least one filler which is isomalt;- at least one binder which is pregelatinized starch;- at least one lubricant which is sodium stearyl fumarate.The composition of the present invention has an improved final dissolution amount in neutral to medium acidic media and excellent stability.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.